LSTA
LSTA
NASDAQ · Biotechnology

Lisata Therapeutics Inc

$3.40
+0.01 (+0.30%)
As of Jun 30, 10:42 PM ET ·
Financial Highlights (FY 2026)
Revenue
177.4K
Net Income
-17,283,339
Gross Margin
9.6%
Profit Margin
-9,756.5%
Rev Growth
-78.8%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 9.6% 9.6% 60.2% 60.2%
Operating Margin -10,711.2% -9,640.1% -3.8% -3.7%
Profit Margin -9,756.5% -9,268.7% -3.8% -3.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 177.4K 838.5K 5.21M 4.72M
Gross Profit 17.0K 80.2K 3.14M 2.84M
Operating Income -19,003,989 -80,829,820 -199,396 -176,250
Net Income -17,283,339 -73,511,366 -195,079 -179,711
Gross Margin 9.6% 9.6% 60.2% 60.2%
Operating Margin -10,711.2% -9,640.1% -3.8% -3.7%
Profit Margin -9,756.5% -9,268.7% -3.8% -3.8%
Rev Growth -78.8% -78.8% -0.3% +24.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 21.25M 18.39M
Total Equity 13.67M 13.06M
D/E Ratio 1.55 1.41
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -18,822,210 -84,504,250 -244,954 -200,080
Free Cash Flow -167,798 -115,643